MovDisordV3, Main, Exploration, bibRecord, 001332

The effect of drug treatment on neurogenesis in Parkinson's disease

Identifieur interne : 001332 ( Main/Exploration ); précédent : 001331; suivant : 001333

The effect of drug treatment on neurogenesis in Parkinson's disease

Auteurs : Sean S. O'Sullivan [Royaume-Uni] ; Mary Johnson [Royaume-Uni] ; David R. Williams [Australie] ; Tamas Revesz [Royaume-Uni] ; Janice L. Holton [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Elaine K. Perry [Royaume-Uni]

Source :

Movement Disorders [ 0885-3185 ] ; 2011-01.

RBID : ISTEX:20400833E0FC8F49CC3E88C9892ACBD539242333

Descripteurs français

Pascal (Inist)
- Cellule souche, Maladie de Parkinson, Pathologie du système nerveux, Traitement.
Wicri :
- topic : Cellule souche.

English descriptors

KwdEn :
- Aged, Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Cell Differentiation (drug effects), Cerebral Ventricles (pathology), Female, Gene Expression Regulation (drug effects), Humans, Levodopa (pharmacology), Levodopa (therapeutic use), Male, Middle Aged, Nerve Tissue Proteins (metabolism), Nervous system diseases, Neural Stem Cells (drug effects), Neurogenesis (drug effects), Neurogenesis (physiology), Parkinson Disease (drug therapy), Parkinson Disease (pathology), Parkinson Disease (physiopathology), Parkinson disease, Parkinson's disease, Postmortem Changes, RNA-Binding Proteins (metabolism), Regression Analysis, Retrospective Studies, Stem cell, Treatment, neurogenesis, neuroprotection, stem cells.
MESH :
- chemical , metabolism : Nerve Tissue Proteins, RNA-Binding Proteins.
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug effects : Cell Differentiation, Gene Expression Regulation, Neural Stem Cells, Neurogenesis.
- drug therapy : Parkinson Disease.
- pathology : Cerebral Ventricles, Parkinson Disease.
- physiology : Neurogenesis.
- physiopathology : Parkinson Disease.
- Aged, Female, Humans, Male, Middle Aged, Postmortem Changes, Regression Analysis, Retrospective Studies.

Abstract

There has been recent interest in the possibility that impaired neurogenesis may contribute to the decline in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease (PD). We have investigated the effects of commonly used treatments for PD on neural stem cell (NSC) activity in nondemented patients. Postmortem of brain tissue containing the subventricular zone (SVZ) and ependymal layer cells was obtained from 32 nondemented patients with PD. NSC activity was assessed by immunohistochemical staining for RNA‐binding protein Musashi1. Regression analyses were then used to identify which clinical factors independently influenced NSC activity. Disease duration was negatively associated with SVZ Musashi1 staining, whereas lifetime levodopa was positively associated in this region. Our findings suggest a positive impact of chronic L‐dopa use on the number of NSC in the SVZ of PD patients, which may have relevance for future studies on neuroprotection in neurodegenerative diseases. © 2010 Movement Disorder Society.

Url:

https://api.istex.fr/document/20400833E0FC8F49CC3E88C9892ACBD539242333/fulltext/pdf

DOI: 10.1002/mds.23340

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The effect of drug treatment on neurogenesis in Parkinson's disease</title>
<author><name sortKey="O Sullivan, Sean S" sort="O Sullivan, Sean S" uniqKey="O Sullivan S" first="Sean S." last="O'Sullivan">Sean S. O'Sullivan</name>
</author>
<author><name sortKey="Johnson, Mary" sort="Johnson, Mary" uniqKey="Johnson M" first="Mary" last="Johnson">Mary Johnson</name>
</author>
<author><name sortKey="Williams, David R" sort="Williams, David R" uniqKey="Williams D" first="David R." last="Williams">David R. Williams</name>
</author>
<author><name sortKey="Revesz, Tamas" sort="Revesz, Tamas" uniqKey="Revesz T" first="Tamas" last="Revesz">Tamas Revesz</name>
</author>
<author><name sortKey="Holton, Janice L" sort="Holton, Janice L" uniqKey="Holton J" first="Janice L." last="Holton">Janice L. Holton</name>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name>
<affiliation><country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
<author><name sortKey="Perry, Elaine K" sort="Perry, Elaine K" uniqKey="Perry E" first="Elaine K." last="Perry">Elaine K. Perry</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:20400833E0FC8F49CC3E88C9892ACBD539242333</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23340</idno>
<idno type="url">https://api.istex.fr/document/20400833E0FC8F49CC3E88C9892ACBD539242333/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001C23</idno>
<idno type="wicri:Area/Istex/Curation">001C23</idno>
<idno type="wicri:Area/Istex/Checkpoint">000064</idno>
<idno type="wicri:doubleKey">0885-3185:2011:O Sullivan S:the:effect:of</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:21322018</idno>
<idno type="wicri:Area/PubMed/Corpus">001440</idno>
<idno type="wicri:Area/PubMed/Curation">001440</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001046</idno>
<idno type="wicri:Area/Ncbi/Merge">002F80</idno>
<idno type="wicri:Area/Ncbi/Curation">002F80</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002F80</idno>
<idno type="wicri:Area/Main/Merge">001385</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:11-0143216</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000741</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002577</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000371</idno>
<idno type="wicri:doubleKey">0885-3185:2011:O Sullivan S:the:effect:of</idno>
<idno type="wicri:Area/Main/Merge">001961</idno>
<idno type="wicri:Area/Main/Curation">001332</idno>
<idno type="wicri:Area/Main/Exploration">001332</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The effect of drug treatment on neurogenesis in Parkinson's disease</title>
<author><name sortKey="O Sullivan, Sean S" sort="O Sullivan, Sean S" uniqKey="O Sullivan S" first="Sean S." last="O'Sullivan">Sean S. O'Sullivan</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Queen Square Brain Bank for Neurological Disorders and Institute of Neurology, University College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Johnson, Mary" sort="Johnson, Mary" uniqKey="Johnson M" first="Mary" last="Johnson">Mary Johnson</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute for Ageing and Health, Newcastle University, Campus for Ageing and Vitality, Newcastle‐upon‐Tyne</wicri:regionArea>
<wicri:noRegion>Newcastle‐upon‐Tyne</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Williams, David R" sort="Williams, David R" uniqKey="Williams D" first="David R." last="Williams">David R. Williams</name>
<affiliation wicri:level="1"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Faculty of Medicine (Neuroscience), Monash University (Alfred Hospital Campus), Melbourne</wicri:regionArea>
<wicri:noRegion>Melbourne</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Revesz, Tamas" sort="Revesz, Tamas" uniqKey="Revesz T" first="Tamas" last="Revesz">Tamas Revesz</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Queen Square Brain Bank for Neurological Disorders and Institute of Neurology, University College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Holton, Janice L" sort="Holton, Janice L" uniqKey="Holton J" first="Janice L." last="Holton">Janice L. Holton</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Queen Square Brain Bank for Neurological Disorders and Institute of Neurology, University College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Queen Square Brain Bank for Neurological Disorders and Institute of Neurology, University College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
<author><name sortKey="Perry, Elaine K" sort="Perry, Elaine K" uniqKey="Perry E" first="Elaine K." last="Perry">Elaine K. Perry</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute for Ageing and Health, Newcastle University, Campus for Ageing and Vitality, Newcastle‐upon‐Tyne</wicri:regionArea>
<wicri:noRegion>Newcastle‐upon‐Tyne</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-01">2011-01</date>
<biblScope unit="vol">26</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="45">45</biblScope>
<biblScope unit="page" to="50">50</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">20400833E0FC8F49CC3E88C9892ACBD539242333</idno>
<idno type="DOI">10.1002/mds.23340</idno>
<idno type="ArticleID">MDS23340</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Cell Differentiation (drug effects)</term>
<term>Cerebral Ventricles (pathology)</term>
<term>Female</term>
<term>Gene Expression Regulation (drug effects)</term>
<term>Humans</term>
<term>Levodopa (pharmacology)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nerve Tissue Proteins (metabolism)</term>
<term>Nervous system diseases</term>
<term>Neural Stem Cells (drug effects)</term>
<term>Neurogenesis (drug effects)</term>
<term>Neurogenesis (physiology)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (pathology)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Postmortem Changes</term>
<term>RNA-Binding Proteins (metabolism)</term>
<term>Regression Analysis</term>
<term>Retrospective Studies</term>
<term>Stem cell</term>
<term>Treatment</term>
<term>neurogenesis</term>
<term>neuroprotection</term>
<term>stem cells</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Nerve Tissue Proteins</term>
<term>RNA-Binding Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Differentiation</term>
<term>Gene Expression Regulation</term>
<term>Neural Stem Cells</term>
<term>Neurogenesis</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Cerebral Ventricles</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Neurogenesis</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Postmortem Changes</term>
<term>Regression Analysis</term>
<term>Retrospective Studies</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cellule souche</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Cellule souche</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">There has been recent interest in the possibility that impaired neurogenesis may contribute to the decline in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease (PD). We have investigated the effects of commonly used treatments for PD on neural stem cell (NSC) activity in nondemented patients. Postmortem of brain tissue containing the subventricular zone (SVZ) and ependymal layer cells was obtained from 32 nondemented patients with PD. NSC activity was assessed by immunohistochemical staining for RNA‐binding protein Musashi1. Regression analyses were then used to identify which clinical factors independently influenced NSC activity. Disease duration was negatively associated with SVZ Musashi1 staining, whereas lifetime levodopa was positively associated in this region. Our findings suggest a positive impact of chronic L‐dopa use on the number of NSC in the SVZ of PD patients, which may have relevance for future studies on neuroprotection in neurodegenerative diseases. © 2010 Movement Disorder Society.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement><li>Londres</li>
</settlement>
<orgName><li>National Hospital for Neurology and Neurosurgery</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="O Sullivan, Sean S" sort="O Sullivan, Sean S" uniqKey="O Sullivan S" first="Sean S." last="O'Sullivan">Sean S. O'Sullivan</name>
</region>
<name sortKey="Holton, Janice L" sort="Holton, Janice L" uniqKey="Holton J" first="Janice L." last="Holton">Janice L. Holton</name>
<name sortKey="Johnson, Mary" sort="Johnson, Mary" uniqKey="Johnson M" first="Mary" last="Johnson">Mary Johnson</name>
<name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name>
<name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name>
<name sortKey="O Sullivan, Sean S" sort="O Sullivan, Sean S" uniqKey="O Sullivan S" first="Sean S." last="O'Sullivan">Sean S. O'Sullivan</name>
<name sortKey="Perry, Elaine K" sort="Perry, Elaine K" uniqKey="Perry E" first="Elaine K." last="Perry">Elaine K. Perry</name>
<name sortKey="Revesz, Tamas" sort="Revesz, Tamas" uniqKey="Revesz T" first="Tamas" last="Revesz">Tamas Revesz</name>
</country>
<country name="Australie"><noRegion><name sortKey="Williams, David R" sort="Williams, David R" uniqKey="Williams D" first="David R." last="Williams">David R. Williams</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001332 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001332 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:20400833E0FC8F49CC3E88C9892ACBD539242333
   |texte=   The effect of drug treatment on neurogenesis in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

The effect of drug treatment on neurogenesis in Parkinson's disease

The effect of drug treatment on neurogenesis in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.